The newest addition to the MSAB, Dr. Painter is a Venture Partner at Even One Ventures, an investment firm focused on advancing patient-first personalized medicines and technologies. Trained in structural biochemistry and cancer immunology, the diagnosis of a very rare, potentially lethal cancer (angiosarcoma) led Dr. Painter to expand her focus to include patient advocacy and the development of novel patient-partnered research models for clinical discovery. She co-founded and served as Deputy Director of the Count Me In research initiative, led by the Broad Institute of M.I.T. and Harvard, which enabled direct-to-patient clinical trial enrollment and facilitated transformative large-scale genomics studies and the implementation of precision treatment strategies for rare cancers. Dr. Painter gave an inspiring keynote talk at the FCF’s inaugural Fibrolamellar Patient & Research Summit in April 2024.